Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | WRN | Q14191 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257396 | 0.91 | GRM4 (0.43) | GRM4HTR2BSLC10A1MAPTTP53 | |
| SCHEMBL17700686 | 0.91 | GRM4 (0.41) | GRM4HTR2BSLC10A1MAPTAR | |
| SCHEMBL17700964 | 0.91 | GRM4 (0.41) | GRM4HTR2BSLC10A1ABCC9ABCC8 | |
| SCHEMBL16257389 | 0.91 | GRM4 (0.41) | GRM4HTR2BSLC10A1ABCC9ABCC8 | |
| SCHEMBL16257319 | 0.91 | GRM4 (0.41) | GRM4HTR2BSLC10A1ABCC9ABCC8 | |
| SCHEMBL17700898 | 0.91 | GRM4 (0.41) | GRM4HTR2BSLC10A1ABCC9ABCC8 | |
| SCHEMBL16257404 | 0.90 | GRM4 (0.44) | GRM4HTR2BSLC10A1MAPTTP53 | |
| SCHEMBL18407949 | 0.89 | GRM4 (0.41) | GRM4SLC10A1ABCC9ABCC8KCNJ11 | |
| SCHEMBL16257431 | 0.88 | HTR2B (0.55) | HTR2BMAPTTP53LMNAGSTO1 | |
| SCHEMBL16257270 | 0.87 | GRM4 (0.40) | GRM4SLC10A1ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305116-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2022-09-29 | — | — | US | claimed |
| WO-2020255012-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | claimed |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-29 | — | — | US | claimed |
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-24 | — | — | US | claimed |
| US-9884818-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | claimed |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | claimed |
| US-20220305116-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. | 2021-09-16 | — | — | US | disclosed |
| WO-2020255012-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-20200332297-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-06 | — | — | US | disclosed |
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-24 | — | — | US | disclosed |
| US-9884818-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| US-9884818-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| EP-3121164-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| WO-2014184350-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | GRM4 2826/4885HTR2B 4279/4885SLC10A1 22/4885 |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, EIF2AK2, IFNAR1 | GRM4 2413/4885HTR2B 4673/4885SLC10A1 499/4885 |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, XDH, HBS1L | GRM4 2826/4885HTR2B 4279/4885SLC10A1 22/4885 |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | GRM4 2826/4885HTR2B 4279/4885SLC10A1 22/4885 |
| US-20220305116-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | HAVCR2, HCCS, IRF3 | GRM4 1761/4885HTR2B 4589/4885SLC10A1 52/4885 |
| US-20200332297-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, EIF2AK2 | GRM4 2542/4885HTR2B 4761/4885SLC10A1 247/4885 |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | GRM4 2826/4885HTR2B 4279/4885SLC10A1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.